Abstract
Relevance: Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. HCC is one of the most important problems
 of the oncology service of Kazakhstan, as it has a progressive course, late detection, low survival, and unfavorable prognosis.
 The study aimed to evaluate the use of targeted immunotherapy in treating hepatocellular carcinoma in a clinical example.
 Methods: The paper presents a clinical case of targeted immunotherapy in combination with Atezolizumab 1200 mg + Bevacizumab 800 mg,
 once every 3 weeks, in treating HCC in the Regional Oncology Center in Kyzylorda.
 Results: The first symptoms of liver damage appeared in 2018, at which time HCC was discovered. Viral hepatitis B was diagnosed in 2016.
 MRI OBP from 15.08.20: a picture of the right lobe of the liver in S5 – 9×7×6 cm, in S3 – 3.7 cm, in S7 – 3.0 cm, in S8 – 2.5 cm. During the follow-up
 examination (July 2021), the enzyme immunoassay revealed a high angiotensin-converting enzyme (ACE) level of 450.56 IU/ml; the abdominal CT
 scan showed no deterioration. Later, despite the therapy, ACE increased rapidly: 2,595.3 IU/ml (August 2021) and 2,142.25 IU/ml (September 2021),
 and the therapy was changed to Regorafenib. ACE continued to rise to 4,405 IU/ml (November 2021) and 18,005 IU/ml (December 2021). A control
 abdominal CT scan showed a moderate reduction in the size of the tumor.
 Taking into account a steady ACE increase, in February 2022, the patient was recommended therapy with Atezolizumab and Bevacizumab. In
 January 2023, the patient has already received 13 courses, and ACE continued to decrease: 1,932 IU/ml (January 2023), 53.38 IU/ml (February
 2023), 16.07 IU/ml (March 2023), and the abdominal CT scan showed positive dynamics.
 Conclusion: Targeted immunotherapy showed its effectiveness in the described case of inoperable HCC and allowed the patient to continue
 living, working, and leading an active lifestyle for more than 18 months.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.